CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal
March 26 2020 - 11:05AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy
company, announced the closing of the offering of 630,500
shares of its common stock at a price of $12.22 per share, for
total gross proceeds of approximately $7.7 million, before
deducting underwriting discounts and other offering expenses
payable by the Company. Additionally, the Company has granted the
underwriter a 45-day option to purchase up to 94,575 additional
shares to cover over-allotments.
Aegis Capital Corp. acted as the sole book-running manager for
the offering.
This offering was made pursuant to a "shelf" registration
statement on Form S-3 (File No. 333-226558) filed with the
Securities and Exchange Commission (SEC). A prospectus supplement
and accompanying base prospectus relating to the offering were
filed with the SEC and are available on the SEC's website at
http://www.sec.gov and may be obtained from Aegis Capital Corp.,
Attention: Syndicate Department, 810 7th Avenue, 18th floor, New
York, NY 10019, by email at syndicate@aegiscap.com, or by telephone
at (212) 813-1010.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management’s current expectations and are subject to risks and
uncertainties that are often difficult to predict, are beyond the
company’s control, and which may cause results to differ materially
from expectations. Accordingly, investors should not to place undue
reliance on these forward-looking statements, which are based on
our expectations as of the date of this press release and speak
only as of the date of this press release. For a discussion of the
most significant risks and uncertainties associated with the
Company’s business, investors are urged to review the company’s
filings with the SEC, including but not limited to its amended
report on Form 10-K/A for the year ended September 30, 2019. Except
as required by law, the Company undertakes no duty to update any
forward-looking statement made herein, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005465/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024